Evidence mapPaperPMID 41848496Full record

ArticleAngewandte Chemie (International ed. in English)2026

Structural Mechanism of an Efficacy Photoswitch Targeting the β

Robin Stipp, Quentin Bertrand, Matilde Trabuco, Anna Duran-Corbera, Maria Tindara Ignazzitto, Hannah Glover, Fabienne Stierli, Juanlo Catena, Melissa Carrillo, Sina Hartmann and 20 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Advances in the Association Between theCurrent issues in molecular biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Robin StippPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Quentin BertrandPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Matilde TrabucoLeadXpro AG, Villigen, Switzerland.
Anna Duran-CorberaMCS, Laboratory of Medicinal Chemistry, Institute For Advanced Chemistry of Catalonia (IQAC), CSIC, Barcelona, Spain.
Maria Tindara IgnazzittoMCS, Laboratory of Medicinal Chemistry, Institute For Advanced Chemistry of Catalonia (IQAC), CSIC, Barcelona, Spain.
Hannah GloverPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Fabienne StierliPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Juanlo CatenaMCS, Laboratory of Medicinal Chemistry, Institute For Advanced Chemistry of Catalonia (IQAC), CSIC, Barcelona, Spain.
Melissa CarrilloPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Sina HartmannPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Hans-Peter SeidelPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Matthias MulderPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Thomas MasonPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Yasushi KondoPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Maximillian WranikPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Martin ApplebyPSI Center for Photon Science, Paul Scherrer Institute, Villigen, Switzerland.
Christoph SagerLeadXpro AG, Villigen, Switzerland.
Raymond SierraLinac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California, USA.
Gregory GateLinac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California, USA.
Pamela SchleissnerLinac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California, USA.
Xinxin ChengLinac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California, USA.
Tobias WeinertPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Robert ChengLeadXpro AG, Villigen, Switzerland.
Sandra MousLinac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California, USA.
John H BealePSI Center for Photon Science, Paul Scherrer Institute, Villigen, Switzerland.
Michal KepaPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.
Amadeu LlebariaMCS, Laboratory of Medicinal Chemistry, Institute For Advanced Chemistry of Catalonia (IQAC), CSIC, Barcelona, Spain.
Michael HennigLeadXpro AG, Villigen, Switzerland.
Xavier RoviraMCS, Laboratory of Medicinal Chemistry, Institute For Advanced Chemistry of Catalonia (IQAC), CSIC, Barcelona, Spain.
Joerg StandfussPSI Center for Life Sciences, Paul Scherrer Institute, Villigen, Switzerland.ORCID 0000-0001-8825-386X

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca SGR 00508Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya, 2021 20228AT014Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya, 2021 SGR 00508Ministerio de Ciencia e Innovación RYC2020-029485-IMinisterio de Ciencia e Innovación and Agencia Estatal de Investigación and ERDF-A way of making Europe PID2020-120499RB-I00Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación and ERDF-A way of making Europe RYC2020-029485-IMinisterio de Ciencia, Innovación y Universidades PID2023-151614NB-I00Ministerio de Ciencia, Innovación y Universidades PID2023-152950OB-I00NIH HHS S10 OD025079Swiss Innovation Agency Innosuisse 42711.1Swiss Nanoscience Institute 1904Swiss National Science Foundation Project 310030_197674Swiss National Science Foundation Project 310030_207462Swiss National Science Foundation Sinergia CRSII5_213507
6 · The paper itself

Abstract

The field of photopharmacology develops light-responsive drugs that can modulate protein activity, enabling precise and dynamic investigations of their roles in health and disease. Adrenergic receptors are prominent targets for this approach because they are prototypical G protein-coupled receptors with high clinical relevance in bronchial and cardiovascular diseases. Here, we employed the azobenzene-based compound photoazolol-1 in combination with time-resolved serial crystallography at X-ray free-electron lasers to resolve the molecular mechanisms by which photoswitchable β-blockers modulate activity of the β

Indexed as

Adrenergic beta-2 Receptor AntagonistsAzo CompoundsReceptors, Adrenergic, beta-2Crystallography, X-RayHumansLightAdrenergic beta-2 Receptor AntagonistsazobenzeneAzo CompoundsReceptors, Adrenergic, beta-2activity modulationazobenzene photoswitchesG protein‐coupled receptorsphotopharmacologytime‐resolved serial femtosecond crystallography

Identifiers

PMID41848496
PMCPMC13110768

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.